Exploring biomarkers in neurological diseases
Application of Biomarkers in Neurological Diseases
This study is trying to find new signs in brain and body samples that could help doctors diagnose and predict the outcomes of neurological diseases better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | The First Hospital of Jilin University Academic / other |
| Locations | 1 site (Changchun, Jilin) |
| Trial ID | NCT05881226 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of biomarkers in diagnosing and predicting outcomes in patients with neurological diseases. Utilizing advanced omics technologies, including proteomics and metabolomics, researchers will analyze brain tissue, plasma, and cerebrospinal fluid (CSF) samples to identify potential biomarkers. The goal is to enhance understanding of the pathogenesis and facilitate early diagnosis of neurological conditions. The research aims to address key challenges in the identification and characterization of biomarkers in both healthy individuals and patients.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with various neurological diseases who are willing to participate and provide informed consent.
Not a fit: Patients currently participating in other clinical investigations or those with poor treatment compliance may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and treatment strategies for neurological diseases.
How similar studies have performed: While research on biomarkers in neurological diseases is ongoing, this study aims to explore novel approaches that are still in the early stages of investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with neurological diseases; 2. Subjects or legal agents agree to participate in the study and sign the informed consent. Exclusion Criteria: 1. Participating in other clinical investigators; 2. Unwilling to be followed up or poor treatment compliance; 3. Other conditions considered unsuitable for inclusion by the researchers.
Where this trial is running
Changchun, Jilin
- First Hospital of Jilin University — Changchun, Jilin, China (Recruiting)
Study contacts
- Study coordinator: Yi YY Yang, Ph.D.
- Email: doctoryangyi@163.com
- Phone: 18186872986
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.